Stocktoria
Ceribell, Inc. CBLL
Ceribell, Inc. (CBLL) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $89.1M at a -60.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.43 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.856 |
| Retained earnings / assets | -1.125 |
| EBIT / assets | -0.298 |
| Equity / liabilities | 3.839 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| BLFS | BIOLIFE SOLUTIONS INC | 6/9 | 10.32 | — | +28.9% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 46.4 | +17% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
About Ceribell, Inc.
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
FAQ
Is CBLL financially healthy?
Ceribell, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CBLL pay a dividend?
No, Ceribell, Inc. does not currently pay a dividend.
How profitable is CBLL?
In FY2025, Ceribell, Inc. had a net margin of -60.0% and a return on equity of -34.4%.
What is the analyst price target for CBLL?
The average Wall-Street price target for Ceribell, Inc. is $26.86, about 17.2% above the recent price, from 7 analysts.
Is CBLL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Ceribell, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.